Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
38.84
-0.65 (-1.65%)
Sep 3, 2026, 3:36 PM EDT - Market open
Immunovant Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 797.8 | 902.11 | 713.97 | 635.37 | 376.53 | 493.82 |
Cash & Short-Term Investments | 797.8 | 902.11 | 713.97 | 635.37 | 376.53 | 493.82 |
Cash Growth | 33.21% | 26.35% | 12.37% | 68.74% | -23.75% | 23.41% |
Accounts Receivable | - | - | - | - | 0.7 | 12.23 |
Other Receivables | 0.7 | 3.95 | 2.51 | 5.5 | 0.19 | 0.63 |
Receivables | 0.7 | 3.95 | 2.51 | 5.5 | 0.89 | 12.86 |
Prepaid Expenses | 52.68 | 42.76 | 51.18 | 24.9 | 26.92 | 6.25 |
Total Current Assets | 851.18 | 948.82 | 767.66 | 665.77 | 404.33 | 512.93 |
Property, Plant & Equipment | 0.35 | 0.52 | 0.94 | 0.6 | 1.51 | 2.63 |
Other Long-Term Assets | 0.96 | 7.68 | 7.62 | - | - | - |
Total Assets | 852.49 | 957.01 | 776.22 | 666.37 | 405.84 | 515.56 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 10.14 | 7.54 | 17.66 | 7.16 | 1.35 | 18.63 |
Accrued Expenses | 64.48 | 96.63 | 50.75 | 41.3 | 40.42 | 24.58 |
Current Portion of Leases | - | 0.07 | 0.1 | 0.14 | 1.17 | 1.15 |
Other Current Liabilities | 42.48 | 0.18 | 0.27 | 0.02 | 0.35 | 0.17 |
Total Current Liabilities | 117.1 | 104.42 | 68.78 | 48.61 | 43.3 | 44.52 |
Long-Term Leases | - | - | - | - | 0.05 | 1.22 |
Total Liabilities | 117.1 | 104.42 | 68.78 | 48.61 | 43.34 | 45.74 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 2,633 | 2,597 | 1,945 | 1,442 | 927.98 | 824.8 |
Retained Earnings | -1,898 | -1,745 | -1,240 | -825.68 | -566.35 | -355.39 |
Comprehensive Income & Other | 0.73 | 0.73 | 1.46 | 1.91 | 0.85 | 0.4 |
Shareholders' Equity | 735.39 | 852.59 | 707.45 | 617.76 | 362.49 | 469.83 |
Total Liabilities & Equity | 852.49 | 957.01 | 776.22 | 666.37 | 405.84 | 515.56 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | - | 0.07 | 0.1 | 0.14 | 1.22 | 2.36 |
Net Cash (Debt) | 797.8 | 902.04 | 713.87 | 635.23 | 375.31 | 491.45 |
Net Cash Growth | 33.21% | 26.36% | 12.38% | 69.25% | -23.63% | 23.88% |
Net Cash Per Share | 4.17 | 4.94 | 4.71 | 4.60 | 3.05 | 4.48 |
Filing Date Shares Outstanding | 206.55 | 205.31 | 170.92 | 146.05 | 130.41 | 116.51 |
Total Common Shares Outstanding | 206.26 | 203.94 | 170.11 | 145.58 | 130.33 | 116.48 |
Working Capital | 734.08 | 844.4 | 698.89 | 617.16 | 361.04 | 468.41 |
Book Value Per Share | 3.57 | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 |
Tangible Book Value | 735.39 | 852.59 | 707.45 | 617.76 | 362.49 | 469.83 |
Tangible Book Value Per Share | 3.57 | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 |